Drug Trial Radar · NCT05559541
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
33
Actual
Start
Dec 15, 2022
Primary completion
May 31, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
Conditions
- Solid Tumor, Adult
Interventions
AK119Drug
AK119 is an anti-CD73 monoclonal antibody.
AK104Drug
AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first 3 or 4 weeks
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.
- Objective response rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Insitute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.